Kymera Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

KYMR$136.64-1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

STOCKHOLDERS’ EQUITY

For the three months ended June 30, 2026 and 2025

(In thousands, except for share amounts)

Common Stock · AdditionalPaid in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
	Shares	Value	Capital	Deficit	Gain (Loss)	Equity
Balance at March 31, 2025	65,112,714	$7	$1,606,475	$(820,191)	$(58)	786,233
Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $13.5 million	5,044,500	—	237,294	—	—	237,294
Exercise of stock options	278,086	—	7,703	—	—	7,703
Vesting restricted stock	78,013	—	—	—	—	—
Issuance of shares under employee stock purchase plan	44,129	—	1,112	—	—	1,112
Stock-based compensation expense	—	—	15,415	—	—	15,415
Unrealized gain on marketable securities	—	—	—	—	337	337
Net loss	—	—	—	(76,614)	—	(76,614)
Balance at June 30, 2025	70,557,442	$7	$1,867,999	$(896,805)	$279	$971,480
Balance at March 31, 2026	82,182,101	$8	$2,679,018	$(1,135,195)	$(4,194)	$1,539,637
Exercise of stock options	518,649	—	13,383	—	—	13,383
Vesting restricted stock	61,551	—	—	—	—	—
Issuance of shares under employee stock purchase plan	25,952	—	1,472	—	—	1,472
Stock-based compensation expense	—	—	18,938	—	—	18,938
Unrealized loss on marketable securities	—	—	—	—	(2,963)	(2,963)
Net loss	—	—	—	(61,211)	—	(61,211)
Balance at June 30, 2026	82,788,253	$8	$2,712,811	$(1,196,406)	$(7,157)	$1,509,256

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the six months ended June 30, 2026 and 2025

(In thousands, except for share amounts)

Common Stock · AdditionalPaid in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders'
Shares · Value · Capital · Deficit · Gain (Loss) · Equity
Balance at December 31, 2024	64,890,193	$7		$1,591,707		$(754,610)		$(1,485)		$835,619
Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $13.5 million	5,044,500		237,294		—		—		237,294
Exercise of stock options	353,738	—		8,237		—		—		8,237
Vesting restricted stock	224,882	—		—		—		—		—
Issuance of shares under employee stock purchase plan	44,129	—		1,112		—		—		1,112
Stock-based compensation expense	—	—		29,649		—		—		29,649
Unrealized gain on marketable securities	—	—		—		—		1,764		1,764
Net loss	—	—		—		(142,195)			(142,195)
Balance at June 30, 2025	70,557,442	$7		$1,867,999		$(896,805)		$279		$971,480
Balance at December 31, 2025	81,323,532	$8		$2,643,817		$(1,065,961)		$1,800		$1,579,664
Exercise of stock options	1,188,166	—		32,577		—		—		32,577
Vesting restricted stock	250,603	—		—		—		—		—
Issuance of shares under employee stock purchase plan	25,952	—		1,472		—		—		1,472
Stock-based compensation expense	—	—		34,945		—		—		34,945
Unrealized loss on marketable securities	—	—		—		—		(8,957)		(8,957)
Net loss	—	—		—		(130,445)		—		(130,445)
Balance at June 30, 2026	82,788,253	8		2,712,811		(1,196,406)		(7,157)		1,509,256

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.